Daewoong (003090) Stock Price, Fundamentals & Analysis

What 003090 does

Daewoong (003090) is a stock listed on the Korea Exchange in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Founded in 1945 and headquartered in Seongnam-si, South Korea, it operates with a small team of 404 employees. Within the Korean healthcare space, it can be compared to peers such as Celltrion (068270), Hanall Biopharma (009420), and Samsung Biologics (207940).

Key numbers explained

• 15,890 KRW is the current share price, representing the latest trading value of one share.
• -1.3% is the price change today, showing the intraday percentage movement relative to the previous close.
• 667.97B KRW is the market capitalization, the total market value of all outstanding shares.
• 1.26% is the dividend yield, which expresses the annual dividend payment as a percentage of the current share price.
• Dec 29, 2025 is the ex-dividend date, the date on or after which a buyer is no longer entitled to the upcoming dividend.
• 5% is the share of earnings paid out as dividends, indicating the portion of net income distributed to shareholders.
• 0.28 is the beta, a measure of the stock's volatility relative to the overall market; a beta below 1 suggests lower sensitivity to market swings.
• 15,410 – 30,600 is the 52-week price range, showing the lowest and highest traded prices over the past year.
• -28.4% is the price change over the last 52 weeks, reflecting the total return from one year ago to the current price.
• 2.12T KRW is the trailing 12-month revenue, the sum of all revenue reported over the most recent four quarters.
• 8% is the year-over-year revenue growth, showing the percentage increase in revenue compared to the same period a year earlier.
• 8.5% is the profit margin, calculated as net income divided by revenue, showing how much profit the company keeps from each unit of sales.
• 13.4% is the operating margin, which measures operating income as a percentage of revenue, reflecting core business efficiency before interest and taxes.
• 12.9% is the return on equity (ROE), indicating how effectively the company generates profit from shareholders' equity.
• 51.9% is the debt-to-equity ratio, expressing total debt as a percentage of shareholders' equity and indicating the company's financial leverage.

What to watch

Investors tracking Daewoong (003090) may monitor factors common to the Drug Manufacturers - Specialty & Generic industry. Revenue growth and profit margins can be influenced by drug approval cycles, patent expirations, and competition within the Korean and broader Asian pharmaceutical markets. The company's relatively low beta of 0.28 suggests it may exhibit less volatility than the broader market, which can be relevant during periods of market stress. Dividend policy, including the dividend yield of 1.26% and the payout ratio of 5%, may shift based on earnings performance and capital allocation priorities. For those interested in the Korean healthcare ecosystem, it is part of the KOSPI 200 and can be compared with Hanmi Pharm (128940) and Chong Kun Dang (185750).